Feds build biological threat detection network—with intelligence agency oversight
H.R. 4165 — To amend the Public Health Service Act to provide for the inclusion of a biological attribution strategy, and an early warning strategy and implementation plan, in the National Health Security Strategy, and for other purposes. · Filed by Dan Crenshaw (R-TX) · 1 cosponsor · Introduced Jun 26, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the federal government to develop and implement two new strategies: (1) a 'biological attribution strategy' to improve coordination across agencies in identifying the source and origin of biological hazards and pandemic pathogens, and (2) an 'early warning strategy' to detect biological, chemical, and radiological threats early using new diagnostic and sequencing technologies. The bill mandates that these strategies include specific timelines, technology development plans, and coordination among federal agencies, state/local health departments, and private-sector partners.
Why we flagged it
The bill's core function is to mandate federal strategy development and inter-agency coordination for biological threat detection and attribution. It is a planning and governance measure, not a regulatory change or appropriation, designed to strengthen pandemic preparedness infrastructure.
What the text implies
- The 'biological attribution' mandate may expand intelligence-community involvement in public health decisions, potentially blurring lines between epidemiology and national security classification.
- Emphasis on 'wastewater, airports, and transportation hubs' for detection suggests broad environmental and travel surveillance infrastructure that could have privacy implications if not carefully implemented.
The full analysis lists 4 implications of this text.
Who stands to gain
diagnostic and sequencing technology companies; pharmaceutical manufacturers (regulatory exposure); healthcare service providers